Bicycle Therapeutics plc - ADR
$4.10
$-0.03
(-0.73%)
As on 01-Sep-2026 16:00EDT
Market cap
$294 Mln
Revenue (TTM)
$61 Mln
P/E Ratio
--
P/B Ratio
0.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.7
-
Face value
--
-
Shares outstanding
50,554,927
8 Years Aggregate
CFO
$-246.73 Mln
EBITDA
$-458.73 Mln
Net Profit
$-493.47 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Bicycle Therapeutics - ADR
| -42.1 | 6.2 | -12.6 | -44.4 | -42.7 | -35.1 | -- |
|
BSE Sensex*
| -9.6 | -2.0 | 3.1 | -4.7 | 5.4 | 6.0 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Bicycle Therapeutics - ADR
| -49.4 | -22.4 | -38.9 | -51.4 | 239.1 | 90.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Bicycle Therapeutics - ADR
|
4.1 | 294.0 | 61.2 | -190.4 | -308.0 | -34 | -- | 0.6 |
| 82.7 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 260.3 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 71.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.9 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 107.7 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 363.8 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 538.7 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 583.2 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 353.4 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Bicycle Therapeutics - ADR
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include... zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom. Read more
-
CEO & Executive Director
Dr. Kevin Lee M.B.A., Ph.D.
-
CEO & Executive Director
Dr. Kevin Lee M.B.A., Ph.D.
-
Headquarters
Cambridge
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Bicycle Therapeutics - ADR
What is the current share price of Bicycle Therapeutics plc - ADR Today?
The share price of Bicycle Therapeutics plc - ADR is $4.10 (NASDAQ) as of 01-Sep-2026 16:00 EDT. Bicycle Therapeutics plc - ADR has given a return of -42.65% in the last 3 years.
What is the current PB & PE ratio of Bicycle Therapeutics plc - ADR?
Since, TTM earnings of Bicycle Therapeutics plc - ADR is negative, P/E ratio is not available.
The P/B ratio of Bicycle Therapeutics plc - ADR is 0.59 times as on 28-Aug-2026, a 89 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-2.24 |
0.81 |
2024 |
-5.72 |
1.22 |
2023 |
-4.25 |
2.07 |
2022 |
-7.80 |
3.25 |
2021 |
-26.23 |
5.06 |
What is the 52 Week High and Low of Bicycle Therapeutics plc - ADR?
The 52-week high and low of Bicycle Therapeutics plc - ADR are Rs 9.16 and Rs 3.75 as of 02-Sep-2026.
What is the market cap of Bicycle Therapeutics plc - ADR?
Bicycle Therapeutics plc - ADR has a market capitalisation of $ 294 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Bicycle Therapeutics plc - ADR?
Before investing in Bicycle Therapeutics plc - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.